Key result
ESC/EACTS valvular heart disease guidelines introduce Heart Valve Centres and update transcatheter and surgical recommendations.
Why the study?
A new joint ESC and EACTS guideline on the management of valvular heart disease was published in 2017 with updated recommendations and concepts.
Summarizes the key updates in the 2017 ESC/EACTS guidelines for the management of valvular heart disease.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The choice of SAVR or TAVI is not simply based on a risk score or age. The heart team must weigh the risks and benefits of both procedures, particularly in the intermediate risk situation. Discussion should include age, comorbidities, anatomy, and outcomes of the centre for surgery and transcatheter intervention.”
“The treatment of heart valve disease has become more complex over the years, we have more and more treatment options interventionally and surgically, so this requires very high expertise and therefore high volume, high expertise centers with very close collaboration between cardiac surgeons and cardiologists.”
“We have now expanded the indications for transcatheter valves because there is new evidence in the intermediate risk population.”
Summarizes 2017 ESC/EACTS VHD guideline updates; leaves open questions on real-world adoption and outcomes.
Søndergaard et al. (2017) conducted a review in valvular heart disease. ESC/EACTS guidelines on management of valvular heart disease was evaluated. The 2017 ESC/EACTS guidelines on valvular heart disease introduced the concept of Heart Valve Centres and updated recommendations for transcatheter valve treatment, surgery, and medical therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: